Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms (+)-18FP-DTBZ, 18F-FP-Dihydrotatetrabenazine, [18F]FP-(+)- DTBZ + [6] |
Target |
Mechanism VMAT2 inhibitors(Synaptic vesicular amine transporter inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H32FNO3 |
InChIKeyGNKGXQHHUUEYQV-WTHAECTESA-N |
CAS Registry956903-29-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nerve Degeneration | Phase 3 | US | 01 Apr 2012 | |
Nerve Degeneration | Phase 3 | AU | 01 Apr 2012 | |
Parkinson Disease | Phase 3 | US | 01 Apr 2012 | |
Parkinson Disease | Phase 3 | AU | 01 Apr 2012 | |
Parkinsonian Disorders | Phase 3 | TW | - | |
Alzheimer Disease | Phase 2 | US | 01 Mar 2010 | |
Lewy Body Disease | Phase 2 | US | 01 Mar 2010 | |
Striatonigral Degeneration | Phase 2 | US | 01 Mar 2010 | |
Obesity | Phase 1 | US | 01 Dec 2012 | |
Prediabetic State | Phase 1 | US | 01 Dec 2012 |
Phase 2 | 40 | rqerflwejr(xfgezpeqgd) = mlczafhgld miuqjjwayu (hdmkuvcigm, lopwaksrvg - mbnvxotrhs) View more | - | 15 Dec 2017 | |||
Phase 2 | - | 25 | cgkfwzfczk(gkwbjpdlhz) = wyykimoriq edgdyskoqy (igvzmyuxuw, oqitppkbjz - mnswqzxezd) View more | - | 25 Sep 2017 |